USFDA18 Jul 2026, 10:00 am
Cipla Subsidiary Receives One Observation from USFDA Inspection
AI Summary
Cipla Ltd announced that its wholly-owned subsidiary, InvaGen Pharmaceuticals Inc., located in Long Island, New York, underwent a routine current Good Manufacturing Practices (cGMP) inspection by the United States Food and Drug Administration (USFDA). The inspection took place from July 13th to July 17th, 2026. Upon conclusion, the facility received one observation in Form 483. Cipla has stated its commitment to working closely with the USFDA and addressing the observation comprehensively within the stipulated timeframe.
Key Highlights
- USFDA conducted a routine cGMP inspection at Cipla's subsidiary, InvaGen Pharmaceuticals.
- The inspection occurred at the Long Island, NY manufacturing facility.
- One observation was received in Form 483 upon inspection conclusion.
- Cipla commits to addressing the observation with USFDA within the stipulated time.
Price Impact
More from CIPLA